Constitutive Androstane Receptor

Constitutive Androstane Receptor
Name	Constitutive Androstane Receptor
Family	Nuclear receptor superfamily
Gene	NR1I3
Organism	Homo sapiens
Location	Chromosome 1

Constitutive Androstane Receptor

The Constitutive Androstane Receptor is a member of the nuclear receptor superfamily predominantly expressed in the liver and involved in xenobiotic sensing and metabolic regulation. It interacts with co-regulators and DNA response elements to control transcription of enzymes and transporters that affect drug metabolism, bilirubin clearance, and lipid homeostasis. CAR function intersects with pathways studied by researchers at institutions such as National Institutes of Health, Harvard University, and Massachusetts Institute of Technology and has been the subject of collaborative projects with pharmaceutical companies including Pfizer, Roche, and GlaxoSmithKline.

Introduction

CAR was identified through genetic and biochemical screens performed in laboratories associated with University of California, San Francisco, Stanford University, and Scripps Research and is encoded by the NR1I3 gene on Chromosome 1 (human). Early characterization involved methods developed at Cold Spring Harbor Laboratory and sequence comparisons using databases maintained by National Center for Biotechnology Information and European Bioinformatics Institute. The receptor is studied in model organisms available from repositories like Jackson Laboratory and in clinical contexts at centers such as Mayo Clinic and Cleveland Clinic.

Structure and Expression

CAR exhibits the canonical domain architecture of nuclear receptors described in structural studies at Brookhaven National Laboratory and features a DNA-binding domain and a ligand-binding domain resolved by groups at Max Planck Institute and EMBL. Expression profiling performed at Broad Institute and Wellcome Trust Sanger Institute shows highest expression in hepatocytes and detectable levels in tissues examined by Karolinska Institute cohorts. Developmental and zonal hepatic patterns were characterized using technologies advanced at Wellcome Sanger Institute and imaging platforms from GE Healthcare and Siemens Healthineers.

Ligands and Activation Mechanisms

CAR responds to diverse endogenous and xenobiotic ligands identified in screens at Novartis and Merck Research Laboratories, including steroid metabolites and small molecules characterized using mass spectrometry platforms at Thermo Fisher Scientific. Activation mechanisms involve direct ligand binding and indirect pathways mediated by signaling cascades studied by groups at The Scripps Research Institute and University of Cambridge; phosphorylation-dependent nuclear translocation was delineated with contributions from researchers at University of Oxford and Yale University. Functional assays employing reporter systems developed at Addgene and high-throughput screening at Genentech expanded the ligand catalog.

Physiological Roles and Target Genes

CAR regulates genes encoding phase I and phase II enzymes and transporters such as members of the cytochrome P450 family identified in landmark studies at National Cancer Institute, and conjugating enzymes mapped by European Molecular Biology Laboratory. Target genes include CYP2B6 and UGT family members revealed in transcriptomic studies at Dana-Farber Cancer Institute and Johns Hopkins University School of Medicine. CAR’s influence on bilirubin clearance, bile acid homeostasis, and lipid metabolism has been investigated in clinical cohorts at Imperial College London and metabolic centers like Mount Sinai Health System.

Regulation and Post-translational Modifications

Regulatory mechanisms include phosphorylation by kinases characterized at Cold Spring Harbor Laboratory and ubiquitination pathways dissected by teams at Max Planck Institute of Biochemistry and Rockefeller University. SUMOylation and acetylation events affecting CAR activity were reported in studies coordinated with laboratories at University of Toronto and University of Pennsylvania. Cross-talk with signaling networks involving MAPK (mitogen-activated protein kinase) cascade components and nuclear co-regulators described by groups at ETH Zurich and University College London modulates CAR stability and transcriptional output.

Clinical Significance and Pharmacology

CAR-mediated induction of drug-metabolizing enzymes has major implications for drug–drug interactions evaluated in clinical pharmacology trials at Food and Drug Administration and regulatory submissions to European Medicines Agency. Polymorphisms in NR1I3 have been genotyped in population studies by 23andMe, UK Biobank, and consortia including International HapMap Project with associations to variable drug response reported in cohorts from Johns Hopkins University and National Institutes of Health Clinical Center. Pharmacological modulators of CAR are pursued by industry groups at AstraZeneca, Bristol-Myers Squibb, and academic drug discovery centers such as University of North Carolina.

Evolution and Comparative Biology

Comparative genomics performed at University of California, Berkeley and Swiss Institute of Bioinformatics shows NR1I3 orthologs across vertebrates with functional divergence characterized in species studied at University of Tokyo, Monash University, and University of Copenhagen. Evolutionary analyses using phylogenetic methods developed at Stanford University and datasets from Ensembl highlight conserved motifs in the ligand-binding domain, while functional assays in zebrafish and rodents from Max Planck Institute and Columbia University reveal species-specific responses relevant to toxicology testing at Organisation for Economic Co-operation and Development.

Category:Nuclear receptors